Hypomagnesemia Research Paper
PPI Induce hypomagnesemia
Several studies have shown that long-term use of Proton Pump Inhibitors (PPIs) is associated with hypomagnesemia, but yet this association is not well understood. The explanation to this association is that PPI use can inhibit magnesium transport in the intestine. Patients who use PPI in long term can deplete the body magnesium stores and suffer from severe complications of hypomagnesaemia. PPI induced hypomagnesemia such as tetany, convulsions, seizures and cardiac arrhythmias put patients at risk for concomitant secondary electrolyte disturbance such as hypocalcemia (Cundy& Dissanayake, 2008).
FDA recommends that health care providers should consider checking magnesium levels prior to initiating PPIs and periodically
Several studies have shown that long-term use of Proton Pump Inhibitors (PPIs) is associated with hypomagnesemia, but yet this association is not well understood. The explanation to this association is that PPI use can inhibit magnesium transport in the intestine. Patients who use PPI in long term can deplete the body magnesium stores and suffer from severe complications of hypomagnesaemia. PPI induced hypomagnesemia such as tetany, convulsions, seizures and cardiac arrhythmias put patients at risk for concomitant secondary electrolyte disturbance such as hypocalcemia (Cundy& Dissanayake, 2008).
FDA recommends that health care providers should consider checking magnesium levels prior to initiating PPIs and periodically